Document is current
Any future updates will be listed below
-
Authors
Dibley, Lesley http://orcid.org/0000-0001-7964-7672
Hart, Ailsa http://orcid.org/0000-0002-7141-6076
Duncan, Julie
Knowles, Charles H. http://orcid.org/0000-0001-9854-6754
Kerry, Sally http://orcid.org/0000-0002-7181-9107
Lanz, Doris http://orcid.org/0000-0001-9879-3069
Madurasinghe, Vichithranie W. http://orcid.org/0000-0002-3853-3422
Wade, Tiffany http://orcid.org/0000-0001-8071-9426
Terry, Helen
Verjee, Azmina
Fader, Mandy http://orcid.org/0000-0002-0801-543X
Norton, Christine http://orcid.org/0000-0003-2259-0948
-
Funding
Funding for this research was provided by:
Research for Patient Benefit Programme (PB-PG-0613-31033)
- License Information
-
More Information
Article History
Received: 13 March 2020
Accepted: 14 June 2020
First Online: 20 June 2020
Compliance with Ethical Standards
:
: Lesley Dibley has received speaker fees from Janssen, AbbVie, and Eli-Lilly, and consultancy fees from GL Assessments and Crohn’s & Colitis UK. Ailsa Hart has served as consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda. She also serves on the Global Steering Committee for Genentech. Julie Duncan has received speaker fees from Warner Chilcott, Dr Falk pharma, Abbvie, Janssen, Takeda, MSD while an IBD Nurse Manager at Guy’s & St Thomas’s Hospitals Trust. She has been fully employed by Takeda UK Ltd since 2018. Charles Knowles has received speaker fees from, and acted as consultant for, Medtronic. Christine Norton has received speaker fees from Ferring, Takeda, and Tillotts Pharma. Mandy Fader, Sally Kerry, Doris Lanz, Vichithranie Madurasinghe, Tiffany Wade, Helen Terry, and Azmina Verjee have no conflicts of interest to declare.
